candesartan has been researched along with imidapril in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akioka, K; Iwao, H; Kim, S; Omura, T; Takeuchi, K; Teragaki, M; Toda, I; Yamagishi, H; Yoshikawa, J; Yoshiyama, M | 1 |
| Beppu, S; Ishikura, F; Kobayashi, H; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M | 1 |
| Fujisawa, T; Ikegami, H; Kawabata, Y; Nishino, M; Noso, S; Ogihara, T; Ono, M | 1 |
| Anglada, MP; Contreras, EM; Esquerra, EA; Martínez, JO; Palma Gámiz, JL; Pêgo, M; Sagastagoitia Gorostiza, JD | 1 |
| Hata, M; Himi, K; Minami, K; Negishi, N; Niino, T; Sezai, A; Shiono, M; Takayama, T; Takemoto, A; Yoda, M | 1 |
| Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Salvadeo, SA; Santoro, T; Zoppi, A | 1 |
| Cheng, X; Fu, M; Gu, Y; Guo, XM; Jia, XJ; Liao, YH; Wang, L; Wang, M; Wei, F; Wei, YM; Yu, SQ; Zhou, ZH; Zhu, F | 1 |
| Horie, M; Matsumoto, T | 1 |
| Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A | 1 |
5 trial(s) available for candesartan and imidapril
| Article | Year |
|---|---|
Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Imidazolidines; Male; Middle Aged; Tetrazoles; Treatment Outcome | 2005 |
A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicent
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Female; Heart Rate; Humans; Hypertension; Imidazolidines; Male; Middle Aged; Portugal; Severity of Illness Index; Spain; Tetrazoles | 2006 |
Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Endothelium, Vascular; Female; Fibrinolysis; Humans; Hypertension; Imidazolidines; Insulin Resistance; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Signal Transduction; Single-Blind Method; Tetrazoles; Tissue Plasminogen Activator; Treatment Outcome; Young Adult | 2011 |
Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Autoantibodies; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Imidazolidines; Male; Middle Aged; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome | 2011 |
Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Topics: Adolescent; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Cholesterol, HDL; Female; Humans; Hypertension; Imidazolidines; Insulin; Male; Metabolic Syndrome; Middle Aged; Plasminogen Activator Inhibitor 1; Tetrazoles; Triglycerides; Young Adult | 2011 |
4 other study(ies) available for candesartan and imidapril
| Article | Year |
|---|---|
Angiotensin blockade inhibits SIF DNA binding activities via STAT3 after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; Benzimidazoles; Biphenyl Compounds; DNA-Binding Proteins; Heart Ventricles; Hemodynamics; Imidazoles; Imidazolidines; Male; Myocardial Infarction; Organ Size; Phosphorylation; Rats; Rats, Wistar; Sp1 Transcription Factor; STAT3 Transcription Factor; Tetrazoles; Time Factors; Trans-Activators; Tyrosine | 2000 |
Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Coronary Vessels; DNA; DNA-Binding Proteins; Drosophila Proteins; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Enzyme Inhibitors; Guanine Nucleotide Exchange Factors; Imidazoles; Imidazolidines; Immunoblotting; Janus Kinase 1; Janus Kinase 2; Male; Myocardial Infarction; Myocardial Ischemia; Peptidyl-Dipeptidase A; Phosphorylation; Precipitin Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Tetrazoles; Time Factors; Trans-Activators | 2001 |
Vascular protecting effect of angiotensin receptor blocker (ARB) on the radial artery graft.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angioscopy; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Coronary Angiography; Coronary Artery Bypass; Female; Humans; Imidazolidines; Male; Middle Aged; Radial Artery; Tetrazoles; Vascular Patency | 2008 |
Angiotensin-converting enzyme inhibition and fibrinolytic balance.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Endothelium, Vascular; Fibrinolysis; Humans; Hypertension; Imidazolidines; Insulin Resistance; Plasminogen Activator Inhibitor 1; Tetrazoles; Tissue Plasminogen Activator; Treatment Outcome | 2011 |